Joint serum-cerebrospinal fluid population pharmacokinetic modelling and dose optimisation of aciclovir in children aged 0-<18 years

Introduction. Aciclovir is an antiviral widely used to treat herpes simplex virus (HSV) infections, including neonatal HSV encephalitis, where adequate serum and cerebrospinal fluid (CSF) exposure is needed. However, a paediatric population pharmacokinetic (PopPK) model characterising CSF penetration remains absent. Aims. To develop a joint serum–CSF PopPK model in children aged 0–18 years to optimise […]